

Augusto Vaglio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4222487/publications.pdf>

Version: 2024-02-01

208
papers

11,978
citations

25034

57
h-index

30922

102
g-index

212
all docs

212
docs citations

212
times ranked

9675
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1583-1594.	0.9	940
2	Genetically Distinct Subsets within ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2012, 367, 214-223.	27.0	820
3	Retroperitoneal fibrosis. <i>Lancet, The</i> , 2006, 367, 241-251.	13.7	612
4	Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. <i>Blood</i> , 2014, 124, 483-492.	1.4	462
5	Eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. <i>European Journal of Internal Medicine</i> , 2015, 26, 545-553.	2.2	371
6	The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4â€“Related Disease. <i>Arthritis and Rheumatology</i> , 2020, 72, 7-19.	5.6	292
7	Eosinophilic granulomatosis with polyangiitis (<sc>C</sc>hurgâ€“<sc>S</sc>trauss): state of the art. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 261-273.	5.7	214
8	Evidence of autoimmunity in chronic periaortitis: a prospective study. <i>American Journal of Medicine</i> , 2003, 114, 454-462.	1.5	191
9	Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. <i>Blood</i> , 2020, 135, 1929-1945.	1.4	191
10	Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. <i>Lancet, The</i> , 2011, 378, 338-346.	13.7	189
11	Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E970-E979.	7.1	172
12	IgG4 immune response in Churgâ€“Strauss syndrome. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 390-393.	0.9	171
13	HLAâ€“DRB4 as a genetic risk factor for Churgâ€“Strauss syndrome. <i>Arthritis and Rheumatism</i> , 2007, 56, 3159-3166.	6.7	168
14	Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 399-405.	0.9	165
15	Idiopathic retroperitoneal fibrosis: Clinicopathologic features and differential diagnosis. <i>Kidney International</i> , 2007, 72, 742-753.	5.2	164
16	Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. <i>Nature Communications</i> , 2019, 10, 5120.	12.8	160
17	Histiocytoses: emerging neoplasia behind inflammation. <i>Lancet Oncology, The</i> , 2017, 18, e113-e125.	10.7	154
18	Chronic periaortitis: a spectrum of diseases. <i>Current Opinion in Rheumatology</i> , 2005, 17, 34-40.	4.3	145

#	ARTICLE	IF	CITATIONS
19	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	6.2	144
20	SARS-CoV-2 infection among patients with systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , 2020, 19, 102575.	5.8	131
21	Positron emission tomography (PET): Evaluation of chronic periaortitis. <i>Arthritis and Rheumatism</i> , 2005, 53, 298-303.	6.7	128
22	Neutrophil Activation Promotes Fibrinogen Oxidation and Thrombus Formation in Behçet Disease. <i>Circulation</i> , 2016, 133, 302-311.	1.6	125
23	Ear, nose and throat manifestations of Churg-Strauss syndrome. <i>Acta Oto-Laryngologica</i> , 2006, 126, 503-509.	0.9	123
24	Idiopathic Retroperitoneal Fibrosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1880-1889.	6.1	123
25	Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: A new overlap syndrome. <i>Autoimmunity Reviews</i> , 2017, 16, 1036-1043.	5.8	120
26	Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1318-1325.	0.9	119
27	Thrombosis in vasculitis: from pathogenesis to treatment. <i>Thrombosis Journal</i> , 2015, 13, 15.	2.1	112
28	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Current Opinion in Rheumatology</i> , 2014, 26, 16-23.	4.3	110
29	Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. <i>Kidney International</i> , 2013, 84, 1025-1033.	5.2	109
30	The Kidney Donor Profile Index (KDPI) of Marginal Donors Allocated by Standardized Pretransplant Donor Biopsy Assessment: Distribution and Association With Graft Outcomes. <i>American Journal of Transplantation</i> , 2014, 14, 2515-2525.	4.7	105
31	Chronic periaortitis and HLA-DRB1*03: Another clue to an autoimmune origin. <i>Arthritis and Rheumatism</i> , 2006, 55, 126-130.	6.7	102
32	Autoimmune aspects of chronic periaortitis. <i>Autoimmunity Reviews</i> , 2006, 5, 458-464.	5.8	97
33	Uraemic Pruritus. <i>Drugs</i> , 2009, 69, 251-263.	10.9	92
34	A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. <i>Rheumatology</i> , 2011, 50, 899-905.	1.9	89
35	IgG4-related disease: a clinical perspective. <i>Rheumatology</i> , 2020, 59, iii123-iii131.	1.9	84
36	Churg-Strauss syndrome. <i>Current Opinion in Rheumatology</i> , 2012, 24, 24-30.	4.3	83

#	ARTICLE	IF	CITATIONS
37	Chronic periaortitis: a fibro-inflammatory disorder. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 339-353.	3.3	79
38	Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. <i>Rheumatology</i> , 2011, 50, 1823-1827.	1.9	78
39	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	6.2	78
40	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.	5.6	78
41	Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis. <i>Journal of Rheumatology</i> , 2020, 47, 377-386.	2.0	77
42	Retroperitoneal Fibrosis: Evolving Concepts. <i>Rheumatic Disease Clinics of North America</i> , 2007, 33, 803-817.	1.9	74
43	Drug-induced lupus: Traditional and new concepts. <i>Autoimmunity Reviews</i> , 2018, 17, 912-918.	5.8	74
44	Chronic periaortitis: a large-vessel vasculitis?. <i>Current Opinion in Rheumatology</i> , 2011, 23, 1-6.	4.3	73
45	Idiopathic and secondary forms of retroperitoneal fibrosis: A diagnostic approach. <i>Revue De Medecine Interne</i> , 2015, 36, 15-21.	1.0	71
46	ANCA-associated vasculitis in childhood: recent advances. <i>Italian Journal of Pediatrics</i> , 2017, 43, 46.	2.6	71
47	Brief Report: Rituximab for the Treatment of Adult-onset IgA Vasculitis (Henoch-Schönlein). <i>Arthritis and Rheumatology</i> , 2018, 70, 109-114.	5.6	71
48	Eosinophilic myocarditis in a patient with idiopathic hypereosinophilic syndrome: Insights into mechanisms of myocardial cell death. <i>Human Pathology</i> , 2004, 35, 1160-1163.	2.0	70
49	Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. <i>Blood</i> , 2015, 126, 1163-1171.	1.4	69
50	Association of Serum C3 Concentration and Histologic Signs of Thrombotic Microangiopathy with Outcomes among Patients with ANCA-Associated Renal Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2143-2151.	4.5	67
51	¹⁸ F-fluorodeoxyglucose positron emission tomography in the diagnosis and followup of idiopathic retroperitoneal fibrosis. <i>Arthritis and Rheumatism</i> , 2005, 53, 122-125.	6.7	65
52	Asbestos and Smoking as Risk Factors for Idiopathic Retroperitoneal Fibrosis. <i>Annals of Internal Medicine</i> , 2014, 161, 181.	3.9	64
53	Differential Structural Remodeling of the Left Atrial Posterior Wall in Patients Affected by Mitral Regurgitation with or Without Persistent Atrial Fibrillation: A Morphological and Molecular Study. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 271-279.	1.7	63
54	Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference. <i>Autoimmunity Reviews</i> , 2015, 14, 692-702.	5.8	63

#	ARTICLE	IF	CITATIONS
55	Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon- γ (IFN- γ) in Operable Renal Cell Carcinoma (RCC). <i>Journal of Immunotherapy</i> , 2014, 37, 440-447.	2.4	61
56	PTPN22 R620W polymorphism in the ANCA-associated vasculitides. <i>Rheumatology</i> , 2012, 51, 805-812.	1.9	60
57	Reverse Phenotyping after Whole-Exome Sequencing in Steroid-Resistant Nephrotic Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 89-100.	4.5	60
58	Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2246-2259.	0.7	59
59	Gabapentin in the treatment of uremic itch: an index case and a pilot evaluation. <i>Journal of Nephrology</i> , 2005, 18, 86-91.	2.0	59
60	Annexin A1 and Autoimmunity: From Basic Science to Clinical Applications. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1348.	4.1	58
61	Neutrophil Extracellular Traps protein composition is specific for patients with Lupus nephritis and includes methyl-oxidized α -enolase (methionine sulfoxide 93). <i>Scientific Reports</i> , 2019, 9, 7934.	3.3	58
62	Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19). <i>Transplant Infectious Disease</i> , 2020, 22, e13286.	1.7	58
63	Management of Hepatitis C Virus-related Mixed Cryoglobulinemia. <i>American Journal of Medicine</i> , 2010, 123, 400-408.	1.5	57
64	Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 1500-1507.	5.6	57
65	Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1584-1586.	0.9	56
66	Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease. <i>Internal and Emergency Medicine</i> , 2017, 12, 287-299.	2.0	56
67	Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 498-503.	5.6	55
68	Long-term immunotherapy with low-dose interleukin-2 and interferon- γ in the treatment of patients with advanced renal cell carcinoma. <i>Cancer</i> , 2001, 92, 2286-2296.	4.1	53
69	Rituximab therapy for chronic periaortitis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1262-1264.	0.9	53
70	Eosinophilic granulomatosis with polyangiitis: understanding the disease and its management. <i>Rheumatology</i> , 2020, 59, iii84-iii94.	1.9	53
71	Polyreactive Antibodies Developing Amidst Humoral Rejection of Human Kidney Grafts Bind Apoptotic Cells and Activate Complement. <i>American Journal of Transplantation</i> , 2013, 13, 2590-2600.	4.7	52
72	Analysis of the common genetic component of large-vessel vasculitides through a meta-ImmunoChip strategy. <i>Scientific Reports</i> , 2017, 7, 43953.	3.3	52

#	ARTICLE	IF	CITATIONS
73	Retroperitoneal fibrosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 439-448.	3.3	51
74	Brief Report: Interleukin-6 as an Inflammatory Mediator and Target of Therapy in Chronic Periaortitis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2469-2475.	6.7	51
75	ANCA-positive periaortic vasculitis: does it fall within the spectrum of vasculitis?. <i>Journal of Internal Medicine</i> , 2002, 251, 268-271.	6.0	49
76	Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1077-1083.	0.9	49
77	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 80-85.	0.9	47
78	Post-treatment residual tissue in idiopathic retroperitoneal fibrosis: active residual disease or silent "scar"? A study using 18F-fluorodeoxyglucose positron emission tomography. <i>Clinical and Experimental Rheumatology</i> , 2005, 23, 231-4.	0.8	46
79	Outcome and prognostic factors during the course of primary small-vessel vasculitides. <i>Journal of Rheumatology</i> , 2006, 33, 1299-306.	2.0	44
80	Churg-Strauss syndrome. <i>Kidney International</i> , 2009, 76, 1006-1011.	5.2	39
81	Monogenic Autoinflammatory Diseases with Mendelian Inheritance: Genes, Mutations, and Genotype/Phenotype Correlations. <i>Frontiers in Immunology</i> , 2017, 8, 344.	4.8	37
82	Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial. <i>PLoS ONE</i> , 2017, 12, e0185880.	2.5	37
83	Association between idiopathic retroperitoneal fibrosis and autoimmune thyroiditis: A case-control study. <i>Autoimmunity Reviews</i> , 2015, 14, 16-22.	5.8	36
84	Idiopathic Mediastinal Fibrosis: a Systemic Immune-Mediated Disorder. A Case Series and a Review of the Literature. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 446-459.	6.5	36
85	International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1360-1372.	5.6	36
86	Erdheim-Chester disease: a rapidly evolving disease model. <i>Leukemia</i> , 2020, 34, 2840-2857.	7.2	35
87	Retroperitoneal Fibrosis. <i>Medicine (United States)</i> , 2009, 88, 208-210.	1.0	33
88	Erdheim-Chester Disease as a Mimic of IgG4-Related Disease. <i>Medicine (United States)</i> , 2016, 95, e3625.	1.0	33
89	Idiopathic retroperitoneal fibrosis: an update for nephrologists. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1773-1781.	0.7	33
90	Tuberculosis as a Trigger of Retroperitoneal Fibrosis. <i>Clinical Infectious Diseases</i> , 2005, 41, e72-e75.	5.8	32

#	ARTICLE	IF	CITATIONS
91	Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis?. <i>Rheumatology</i> , 2015, 54, 2004-2009.	1.9	32
92	Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-211897.	0.9	32
93	TLR-mediated induction of negative regulatory ligands on dendritic cells. <i>Journal of Molecular Medicine</i> , 2008, 86, 443-455.	3.9	30
94	Eotaxin/CCL11 in idiopathic retroperitoneal fibrosis. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3875-3884.	0.7	29
95	Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives. <i>Internal and Emergency Medicine</i> , 2017, 12, 727-731.	2.0	29
96	Chronic periaortitis associated with membranous nephropathy: clues to common pathogenetic mechanisms. <i>Clinical Nephrology</i> , 2010, 74, 485-490.	0.7	27
97	Adult-onset IgA vasculitis (Henoch-Schönlein): Update on therapy. <i>Presse Medicale</i> , 2020, 49, 104035.	1.9	26
98	CC chemokine receptor 5 polymorphism in chronic periaortitis. <i>Rheumatology</i> , 2011, 50, 1025-1032.	1.9	25
99	Neutrophil Extracellular Traps in the Autoimmunity Context. <i>Frontiers in Medicine</i> , 2021, 8, 614829.	2.6	25
100	IgG4-related disease: a contemporary review. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 1616-1631.	0.9	24
101	Peripheral inflammatory arthritis in patients with chronic periaortitis: report of five cases and review of the literature. <i>Rheumatology</i> , 2007, 47, 315-318.	1.9	23
102	Subclinical Interstitial Lung Abnormalities in Stable Renal Allograft Recipients in the Era of Modern Immunosuppression. <i>Transplantation Proceedings</i> , 2011, 43, 2617-2623.	0.6	23
103	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. <i>RMD Open</i> , 2017, 3, e000449.	3.8	23
104	Pericarditis heralding Erdheim-Chester Disease. <i>Circulation</i> , 2008, 118, e511-2.	1.6	22
105	Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon- γ for metastatic renal cell cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 553-561.	4.2	22
106	Genetic aspects of anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2014, 30 Suppl 1, i37-45.	0.7	22
107	Cardiac involvement in Erdheim-Chester disease: an MRI study. <i>Blood</i> , 2016, 128, 2468-2471.	1.4	22
108	Chronic Periaortitis: an Update. <i>Current Rheumatology Reports</i> , 2018, 20, 80.	4.7	22

#	ARTICLE	IF	CITATIONS
109	Clinical and Prognostic Significance of Serum IgG4 in Chronic Periaortitis. An Analysis of 113 Patients. <i>Frontiers in Immunology</i> , 2019, 10, 693.	4.8	22
110	Prognostic Significance of Albuminuria in Patients With Renal Cell Cancer. <i>Journal of Urology</i> , 2003, 170, 1135-1137.	0.4	21
111	The European Vasculitis Society 2016 Meeting Report. <i>Kidney International Reports</i> , 2017, 2, 1018-1031.	0.8	21
112	Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Rheumatology</i> , 2021, 60, 4355-4360.	1.9	21
113	Aortitis and periaortitis: The puzzling spectrum of inflammatory aortic diseases. <i>Presse Medicale</i> , 2020, 49, 104018.	1.9	21
114	Type I interferon-related kidney disorders. <i>Kidney International</i> , 2022, 101, 1142-1159.	5.2	21
115	Rituximab for chronic periaortitis without evidence of IgG4-related disease: a long-term follow-up study of 20 patients. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 433-434.	0.9	19
116	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). <i>European Respiratory Journal</i> , 2021, 57, 2004158.	6.7	19
117	Prognostic Factors and Long-Term Outcome with ANCA-Associated Kidney Vasculitis in Childhood. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1043-1051.	4.5	19
118	Kidney involvement in medium- and large-vessel vasculitis. <i>Journal of Nephrology</i> , 2016, 29, 495-505.	2.0	18
119	Fcγ3-receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1597-1599.e8.	2.9	18
120	Trends in Immune Cell Function Assay and Donor-Specific HLA Antibodies in Kidney Transplantation: A 3-Year Prospective Study. <i>American Journal of Transplantation</i> , 2013, 13, 3215-3222.	4.7	17
121	A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1662-1665.	2.9	17
122	Fibrocytes in Chronic Periaortitis: A Novel Mechanism Linking Inflammation and Fibrosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1913-1922.	5.6	17
123	The rise of complement in ANCA-associated vasculitis: from marginal player to target of modern therapy. <i>Clinical and Experimental Immunology</i> , 2020, 202, 403-406.	2.6	17
124	Multi-Autoantibody Signature and Clinical Outcome in Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1762-1776.	4.5	17
125	Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 332-340.	2.9	17
126	Into Clinical Practice: Diagnosis and Therapy of Retroperitoneal Fibrosis. <i>Current Rheumatology Reports</i> , 2021, 23, 18.	4.7	17

#	ARTICLE	IF	CITATIONS
127	A Candidate Gene Approach Identifies an IL33 Genetic Variant as a Novel Genetic Risk Factor for GCA. PLoS ONE, 2014, 9, e113476.	2.5	17
128	Role of 18F-fluorodeoxyglucose positron emission tomography in the workup of retroperitoneal fibrosis. Clinical and Experimental Rheumatology, 2011, 29, S72-8.	0.8	17
129	Large Bowel Obstruction heralding Churg-Strauss Syndrome. American Journal of Gastroenterology, 2004, 99, 562-563.	0.4	16
130	Eprodinate in amyloid A amyloidosis: a novel therapeutic approach?. Expert Opinion on Pharmacotherapy, 2008, 9, 2175-2180.	1.8	16
131	Increased viral load after intravenous immunoglobulin therapy for BK virus-associated nephropathy. Transplant Infectious Disease, 2010, 12, 470-472.	1.7	16
132	Post-translational modified proteins are biomarkers of autoimmune-processes: NETosis and the inflammatory "autoimmunity connection. Clinica Chimica Acta, 2017, 464, 12-16.	1.1	16
133	[18 F]-Fluorodeoxyglucose Positron Emission Tomography and Response to Therapy in Idiopathic Retroperitoneal Fibrosis. European Urology, 2018, 73, 145-146.	1.9	16
134	Gabapentin for uraemic pruritus. Nephrology Dialysis Transplantation, 2005, 20, 1278-1279.	0.7	15
135	Retroperitoneal fibrosis associated with psoriasis: a case series. Scandinavian Journal of Rheumatology, 2009, 38, 68-69.	1.1	15
136	Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case. Pediatric Nephrology, 2012, 27, 1995-1999.	1.7	15
137	Manifestations of Skull Base IgG4-Related Disease: A Multi-Institutional Study. Laryngoscope, 2020, 130, 2574-2580.	2.0	15
138	Chronic Periaortitis. Circulation, 2008, 118, 1214-1216.	1.6	14
139	Multifocal phaeohyphomycosis caused by <i>Xophiala xenobiotica</i> in a kidney transplant recipient. Transplant Infectious Disease, 2015, 17, 297-302.	1.7	14
140	Skull Base Manifestations of Erdheim-Chester Disease: A Case Series and Systematic Review. Neurosurgery, 2019, 85, E693-E701.	1.1	14
141	Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T Medicine, 2021, 85, 68-79.	2.2	14
142	Long-term follow-up of mTOR inhibition for Erdheim-Chester disease. Blood, 2020, 135, 1994-1997.	1.4	14
143	EBV-Associated Leukoencephalopathy with Late Onset of Central Nervous System Lymphoma in a Kidney Transplant Recipient. American Journal of Transplantation, 2010, 10, 947-951.	4.7	13
144	First report of FIP1L1-PDGFR±-positive eosinophilic granulomatosis with polyangiitis : Fig. 1. Rheumatology, 2015, 54, 1751-1753.	1.9	13

#	ARTICLE	IF	CITATIONS
145	New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group. <i>Internal and Emergency Medicine</i> , 2019, 14, 1193-1197.	2.0	13
146	Occupational Exposures and Smoking in Eosinophilic Granulomatosis With Polyangiitis: A Caseâ€“Control Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1694-1702.	5.6	13
147	Increased fetuin-A levels following treatment with a vitamin D analog. <i>Kidney International</i> , 2010, 78, 1187.	5.2	12
148	Erdheim-Chester disease: the â€œtargetedâ€•revolution. <i>Blood</i> , 2017, 130, 1282-1284.	1.4	12
149	Effects of nucleases on cell-free extrachromosomal circular DNA. <i>JCI Insight</i> , 2022, 7, .	5.0	12
150	Gabapentin as a therapeutic option in uremic pruritus. <i>Kidney International</i> , 2008, 73, 512.	5.2	11
151	Comparison of PR3-ANCA specific assay performance for the diagnosis of granulomatosis with polyangiitis (Wegenerâ€™s). <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 2141-2149.	2.3	11
152	The evolving paradigm of cancer risk related to cyclophosphamide therapy in granulomatosis with polyangiitis: Table 1. <i>Rheumatology</i> , 2015, 54, 1339-1341.	1.9	11
153	Stem-Cell-Derived Circulating Progenitors Dysfunction in Behçet's Syndrome Patients Correlates With Oxidative Stress. <i>Frontiers in Immunology</i> , 2019, 10, 2877.	4.8	11
154	Collapsing Glomerulopathy as a Complication of Type I Interferonâ€“Mediated Glomerulopathy in a Patient With RNASEH2B-Related Aicardi-GoutiÃ©res Syndrome. <i>American Journal of Kidney Diseases</i> , 2021, 78, 750-754.	1.9	11
155	Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2190-2200.	0.7	11
156	Chronically Administered Immunotherapy with Low-Dose IL-2 and IFN-Î± in Metastatic Renal Cell Carcinoma: A Feasible Option for Patients with a Good Prognostic Profile. <i>Oncology</i> , 2009, 76, 69-76.	1.9	10
157	Immunoglobulin G4-related disease: some missing pieces in a still unsolved complex puzzle. <i>Cardiovascular Pathology</i> , 2016, 25, 90-92.	1.6	10
158	Candida sake as the causative agent of spondylodiscitis in a hemodialysis patient. <i>Spine Journal</i> , 2011, 11, e12-e16.	1.3	9
159	Podocytes and Proteinuria in ANCA-Associated Glomerulonephritis: A Case-Control Study. <i>Frontiers in Immunology</i> , 2019, 10, 1405.	4.8	9
160	Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis. <i>Rheumatology</i> , 2021, 60, 3176-3188.	1.9	9
161	Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1769-1772.	0.9	9
162	Meningeal involvement in apparently ANCA-negative Wegener's granulomatosis: a role for PR3 capture-ELISA?. <i>Rheumatology</i> , 2007, 46, 1375-1376.	1.9	8

#	ARTICLE	IF	CITATIONS
163	TLR-4 and VEGF Polymorphisms in Chronic Periaortitis. PLoS ONE, 2013, 8, e62330.	2.5	8
164	Malignant MÃ¶nckeberg medial calcific sclerosis. Internal and Emergency Medicine, 2018, 13, 615-617.	2.0	8
165	Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part) Tj ETQq1 1 0,784314 rgBT /Over	1.9	8
166	FCGR3B polymorphism predicts relapse risk in eosinophilic granulomatosis with polyangiitis. Rheumatology, 2020, 59, 3563-3566.	1.9	8
167	Peri-renal Collateral Circles. Urology, 2009, 74, 292-293.	1.0	7
168	Randomized trial of two after-dialysis gabapentin regimens for severe uremic pruritus in hemodialysis patients. Internal and Emergency Medicine, 2019, 14, 1341-1346.	2.0	7
169	Hemoptysis in BehÃ¶tÃ¶m's syndrome: from bedside to bench?. Internal and Emergency Medicine, 2018, 13, 467-469.	2.0	6
170	Pure red cell aplasia followed by disseminated intravascular coagulation in a haemodialysis patient receiving erythropoietin-Ã¶. Nephrology Dialysis Transplantation, 2007, 22, 1465-1467.	0.7	5
171	Low-dose tocilizumab for relapsing giant cell arteritis in the elderly, fragile patient: Beyond the GACTA trial. Autoimmunity Reviews, 2018, 17, 1265-1267.	5.8	5
172	Proteinuria selectivity index predicts response to rituximab in adults with minimal change disease and focal segmental glomerulosclerosis. Nephrology Dialysis Transplantation, 2022, 37, 789-791.	0.7	5
173	Tamoxifen Therapy for Retroperitoneal Fibrosis. Annals of Internal Medicine, 2006, 144, 619.	3.9	4
174	Gabapentin use in chronic uraemic itch is in line with emerging pathogenetic hypothesis. Nephrology Dialysis Transplantation, 2007, 22, 3669-3670.	0.7	4
175	FCGR2A single nucleotide polymorphism confers susceptibility to childhood-onset idiopathic nephrotic syndrome. Immunology Letters, 2018, 193, 11-13.	2.5	4
176	Erdheim-Chester disease: A challenging diagnosis for an effective therapy. Clinical Neurology and Neurosurgery, 2020, 194, 105841.	1.4	4
177	Gut Microbiota and Associated Mucosal Immune Response in Eosinophilic Granulomatosis with Polyangiitis (EGPA). Biomedicines, 2022, 10, 1227.	3.2	4
178	Eprodinate in AA Amyloidosis. New England Journal of Medicine, 2007, 357, 1153-1154.	27.0	3
179	Impact of Posttransplant Lymphoproliferative Disorders on Kidney Graft Survival. Transplantation, 2014, 98, e21-e25.	1.0	3
180	The Sound of Interconnectivity; The European Vasculitis Society 2022 Report. Kidney International Reports, 2022, 7, 1745-1757.	0.8	3

#	ARTICLE	IF	CITATIONS
181	Calciphylaxis: evolving concepts. <i>Internal and Emergency Medicine</i> , 2006, 1, 320-322.	2.0	2
182	Microarray evaluation of allergen-specific IgE in eosinophilic granulomatosis with polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1247-1248.	0.9	2
183	FC 039RENAL OUTCOME AFTER RITUXIMAB IN ADULT-ONSET IGA VASCULITIS AND CRESCENTIC IGA NEPHROPATHY: A MULTICENTRE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	2
184	IgG4-related disease: not just a matter of IgG4. <i>Rheumatology</i> , 2021, 60, iii35-iii38.	1.9	2
185	"Late" regressions of metastases from renal cancer after a period of disease progression continuing the same intermittent low dose immunotherapy regimen. <i>Acta Biomedica</i> , 2004, 75, 126-30.	0.3	2
186	New therapeutics for ANCA-associated vasculitis: 10 years devoted to lessen toxicity. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 18-22.	0.8	2
187	Treatment of idiopathic retroperitoneal fibrosis. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 769-777.	0.8	1
188	A misleading diagnosis of granulomatosis with polyangiitis disguising Whipple's disease. <i>Rheumatology</i> , 2018, 57, 1307-1309.	1.9	1
189	ANCA testing: where are we now?. <i>Internal and Emergency Medicine</i> , 2021, 16, 269-271.	2.0	1
190	Pediatric Erdheim-Chester Disease in the Molecular Era: A Multicenter Case Series. <i>Blood</i> , 2021, 138, 4194-4194.	1.4	1
191	A Report of 2 Cases of Kidney Involvement in ADA2 Deficiency: Different Disease Phenotypes and the Tissue Response to Type I Interferon. <i>American Journal of Kidney Diseases</i> , 2022, 80, 677-682.	1.9	1
192	Reply to the letter of Dr A. Janin. <i>Human Pathology</i> , 2005, 36, 593.	2.0	0
193	167 REGULATION OF INNATE AND ADAPTIVE IMMUNE RESPONSES BY HUMAN ARTERIES.. <i>Journal of Investigative Medicine</i> , 2006, 54, S285.5-S285.	1.6	0
194	254 VASCULAR DENDRITIC CELLS IN GIANT CELL ARTERITIS: TRIGGERING OF VASCULAR INFLAMMATION BY TOLL-LIKE RECEPTOR LIGANDS.. <i>Journal of Investigative Medicine</i> , 2006, 54, S301.4-S301.	1.6	0
195	Chronic Periaortitis (CP). <i>Medical Radiology</i> , 2011, , 175-185.	0.1	0
196	Histiocytoses. , 2018, , 379-390.		0
197	FP165SLOWLY PROGRESSIVE ANCA-ASSOCIATED GLOMERULONEPHRITIS: A MULTICENTRE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
198	ANCA-Associated Vasculitis. <i>Rare Diseases of the Immune System</i> , 2019, , 111-128.	0.1	0

#	ARTICLE	IF	CITATIONS
199	P1805UNEXPECTED COMPLEMENT GENES ABNORMALITIES IN CHILDREN WITH SECONDARY HEMOLITIC UREMIC SYNDROME. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
200	Response to: "Eosinophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: a potential mimicker of IgG4-related disease"™ by Akiyama<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e121-e121.	0.9	0
201	Isolated Aortitis and Periaortitis. <i>Rare Diseases of the Immune System</i> , 2021, , 199-209.	0.1	0
202	Editorial: Immune Monitoring Responses in Renal Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 722791.	4.8	0
203	IgG4-related disease and Rosai-Dorfman-Destombes disease " Authors' reply. <i>Lancet, The</i> , 2021, 398, 1214-1215.	13.7	0
204	Retroperitoneal Fibrosis and the Spectrum of Chronic Periaortitis. <i>Rare Diseases of the Immune System</i> , 2017, , 101-115.	0.1	0
205	Miscellaneous Organ Involvement in ANCA-Associated Vasculitis. <i>Rare Diseases of the Immune System</i> , 2020, , 269-292.	0.1	0
206	FC040: Kidney Transplantation in Childhood-Onset ANCA-Associated Vasculitis: Outcomes in a Multicentre Cohort. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
207	FC036: A Clinical Workflow for Selection of Patients and Cost-Efficient Diagnosis of Genetic Kidney Diseases. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
208	MO1057: Cost-Analysis of a Clinical Workflow for Diagnosis of Inherited Kidney Diseases. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0